There is an urgent need for predictive biomarkers in clinical research. Physicians, patients, and payers are demanding more efficacy and safety windows. Due to limited research funds, drug developers are forced to select projects they are confident in early in development to invest in expensive phase II & III studies to investigate further.

Although the need is clear, the most commonly used methods for quantification in serum or plasma samples are more than two decades old. These methods quantify the totality of proteins and overlook new developments and understanding of proteins as complex players that have multiple functions.

Separate quantification of individual protein components provides more information about protein formation, protein degradation, and potential signaling domains than a crude measurement of total protein. In fact, many chronic diseases such as osteoporosis, osteoarthritis, fibrosis of the liver, lung, kidney, skin, intestine and heart are due to an imbalance between tissue formation and degradation.

The Nordic ProteinFingerPrint Technology™

Proteins have multiple domains, each with different functions. Some proteins have pro-peptides that can be used as biomarkers of protein formation. Other proteins have cryptic signals that are released after cleavage by proteases during tissue remodeling. Finally, all proteins are degraded, resulting in specific fragments that can be used as biomarkers for protein destruction. Collagens contain a variety of domains that can be individually quantified and provide a wealth of information. Similar to a fingerprint, when proteins are cleaved, they leave fragments that can be non-invasively identified in serum.

Thus, the Nordic Protein FingerPrint Technology™ is the quantification of the different collagen domains based on the fragments that are released into the bloodstream. Accurate information about tissue formation and degradation can accelerate clinical trial and drug development phases and help find the right treatment for the right patient. Some examples can be found below.

Our research group has been working on the Extracellular Matrix (ECM) and collagens for more than 30 years and has published more than 575 papers.

The N- and C-terminal ends of fibrillar collagens contain pro-peptides, which are cleaved and separated from the molecule when the collagens are embedded into the matrix. The mature collagen structure will only be incorporated correctly into the ECM when the PRO-peptides are removed. The maturation and the correct processing of the collagens are essential for the quality of the ECM structure. The pro-peptides can be used as a surrogate measure of tissue formation. Biomarkers of type I collagen formation (PINP or PICP) have been used for the assessment of bone formation12 for decades. Only the Nordic Bioscience neo-epitope Nordic ProteinFingerPrint Technology™ allows for the assessment of the exact PRO-peptides generated during tissue formation, by measuring the cleavage site neo-epitope generated by proteases in this process. 

In order to sustain healthy tissues, the ECM is continuously being remodeled; as such, associated ECM proteins are degraded. This degradation results in the release of small protein fragments from larger complex proteins and the circulating fragments may be used as biomarkers. The smaller protein fragments contain information relating to specific tissue degradation. For example, bone is continuously remodeled by the bone degrading osteoclasts. The main destructive protease responsible is cathepsin K. The cleavage of type I collagen by cathepsin K yields the fragment referred to as CTX-I, which has been used as a biomarker of bone resorption for diseases in the osteology field3,4.

By assessing the formation and degradation of tissue separately, a greater understanding of tissue homeostasis can be obtained. Traditional protein measurement technologies do not permit the separate assessment of formation and degradation; rather, these methods quantify the total protein pool. In many diseases, the balance between degradation and formation of tissues is affected, leading to more non-functional tissue such as in skin, liver, lung, and kidney fibrosis or increased degradation leading to tissue loss in rheumatologic disorders. The figure below highlights the formation and degradation balance in a healthy individual, as compared to a diseased individual. This balance may be severely altered leading to the same amount of that protein in the blood, but with an altered composition. In COPD, 50% less formation and 50% more degradation is observed during excerbations5,6. This imbalance is not detected by traditional assays, but only by using the Nordic ProteinFingerPrint Technology™7,8.

The extracellular matrix proteins are emerging as more than just passive structural proteins7,8. Collagens and other proteins contain sequences with potent signaling functions and these sequences become active when they are exposed and released by proteolytic cleavage. Assays have been developed for the bioactive fragments of these proteins. See the below examples.



Collagen type



Type IV



Type VI






Type XV




A protein is not just a protein, and a serological assessment of protein fragments - not a pool of the entire protein - may contain essential information for data interpretation since ECM signal peptides, tissue formation and tissue degradation fragments need to be quantified separately. By using more advanced protein assessment technologies, more accurate diagnostic and prognostic information may be obtained. 

1. Henriksen K, Tanko LB, Qvist P, et al: Assessment of osteoclast number and function: Application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18, 2007

2. Karsdal MA, Henriksen K, Leeming DJ, et al: Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. [Internet]. Biomarkers 14:181–202, 2009

3. Garnero P, Ferreras M, Karsdal MA, et al: The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen Degradation. J Bone Miner Res 18, 2003

4. Henriksen K, Bohren KM, Bay-Jensen AC, et al: Should biochemical markers of bone turnover be considered standard practice for safety pharmacology? Biomarkers 15:195–204

5. Sand JMB, Leeming DJ, Byrjalsen I, et al: High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD - results from the ECLIPSE study. Respir Res 17:125, 2016

6. Schumann DM, Leeming D, Papakonstantinou E, et al: Collagen degradation and formation are elevated in exacerbated COPD compared to stable disease. [Internet]. Chest , 2018

7. Sand JMB, Knox AJ, Lange P, et al: Accelerated extracellular matrix turnover during exacerbations of COPD. Respir Res 16, 2015

8. Stolz D, Leeming DJ, Kristensen JHE, et al: Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD. Chest 151, 2017

9. Karsdal MA, Manon-Jensen T, Genovese F, et al: Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 308:G807-30, 2015

10. Karsdal MA, Nielsen SH, Leeming DJ, et al: The good and the bad collagens of fibrosis - Their role in signaling and organ function. [Internet]. Adv Drug Deliv Rev , 2017

11. Karsdal MA, Henriksen K, Genovese F, et al: Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes. Diabetologia 60, 2017

12. Siebuhr AS, Karsdal MA: Type XIII Collagen. 2016

13. Schuppan D, Cramer T, Bauer M, et al: Hepatocytes as a source of collagen type XVIII endostatin. [Internet]. Lancet (London, England) 352:879–80, 1998

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.